Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Cardiometabolic Drug Developments

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on NAMS stock, giving a Buy rating today.

Tyler Van Buren has given his Buy rating due to a combination of factors surrounding NewAmsterdam Pharma’s promising developments with their drug obi. The company has demonstrated significant cardiometabolic benefits across various conditions such as ASCVD, diabetes, and Alzheimer’s disease. Notably, the BROADWAY trial revealed an impressive 21% reduction in major adverse cardiovascular events (MACE) within one year, attributed to obi’s lipid-lowering effects beyond just LDL-C. This includes its impact on LDL-P and Lp(a), which contributed additional benefits.
Furthermore, NewAmsterdam is set to present further data from Phase III trials at upcoming conferences, which are expected to reinforce the positive findings from earlier analyses. The PREVAIL trial will evaluate a comprehensive 4-point MACE as its primary endpoint, with a follow-up period of at least 2.5 years, potentially confirming obi’s efficacy as a leading lipid-lowering therapy. The strategic inclusion of various endpoints aims to secure a broad label for obi, enhancing its market potential. These factors collectively underpin Van Buren’s optimistic outlook on NewAmsterdam Pharma’s stock.